Nick Ziogas, M.D. is an Associate Vice President, Clinical Design, Neuroscience at Eli Lilly and Company. He leads clinical design strategy for Phase 1–3 neuroscience programs, including protocol design, endpoint strategy, biomarker integration, and cross-functional development decision-making.

Before joining Lilly, Nick held clinical development leadership roles at Bristol Myers Squibb and Biogen, where he worked on neurodegenerative disease programs across Alzheimer’s disease, Parkinson’s disease, ALS, and related areas. At Biogen, he was Global Clinical Development Leader for Alzheimer’s disease and contributed to the development of BIIB080, a tau-targeted antisense oligonucleotide investigated in Alzheimer’s disease.

Earlier in his career, Nick was a physician-scientist at Johns Hopkins University School of Medicine, where his research focused on the neuropathological mechanisms of neurodegenerative diseases.

Nick earned his M.D. from the Aristotle University of Thessaloniki and completed a neuropathology fellowship at Johns Hopkins University School of Medicine. He lives in Boston, Massachusetts.